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Abstract
Introduction: Chromogranin A (CgA) is regarded as a major, nonspecific marker of neuroendocrine tumors (NET). Its estimation appears
helpful for diagnostic purposes and is particularly useful for monitoring the treatment of NET. It must be kept in mind, however, that
various factors, drugs, or coexisting diseases may influence the outcome of CgA measurement in blood. One such analytical factor is the
sort of studied biological material, whether it is plasma or serum.
The aim of our study was to compare directly the results of CgA concentrations measured in serum and in plasma by IRMA and ELISA.
Material and methods: We analysed 122 samples of EDTA-plasma and 122 samples of serum by IRMA method, 20 samples of EDTA-
plasma and 20 samples of serum by IRMA and ELISA, 25 heparinised-plasma samples and 25 samples of EDTA-plasma by IRMA and
ELISA methods, and 8 EDTA-plasma, heparinised-plasma, and serum samples by IRMA and ELISA.
The material for comparative study was obtained during the same blood collection from the same subjects (volunteers and patients with
NET). CgA was measured with the use of kits manufactured by CIS bio International (France).
Results: CgA concentrations were markedly higher in plasma than in serum. Using the IRMA method, the difference in the CgA range
between 10–100 ng/mL approached 20–70% (median 61 v. 42), in the range 101–300 ng/mL –— 12–60% (median 147 v. 101), and in the CgA
range 301–1076 ng/mL — 14–40% (median 486 v. 356). The differences between results in serum and plasma using ELISA were similar but
slightly smaller. There was no significant difference between CgA levels in EDTA and heparinised-plasma samples, and the results of
measurements performed by IRMA and ELISA in most cases were similar.
Conclusions: Referring each individual CgA result to the proposed reference range (or cut-off value) we must take into account whether
the measurement is performed in plasma or in serum. (Pol J Endocrinol 2010; 61 (4): 346–350)
Key words: chromogranin A, CgA, CgA-IRMA, CgA-ELISA, neuroendocrine tumours
Streszczenie
Wstęp: Chromogranina A (CgA, chromagranin A) jest głównym, niespecyficznym markerem guzów neuroendokrynnych (NET, neuroendo-
crine tumors). Oznaczanie jej stężenia jest pomocne w diagnostyce biochemicznej oraz szczególnie użyteczne w monitorowaniu efektów
leczenia guzów NET. Istnieje wiele czynników analitycznych, leków i współistniejących chorób mogących wpływać na stężenie CgA we
krwi. Jednym z takich czynników może być rodzaj użytego materiału biologicznego do badania, to znaczy czy jest to osocze czy surowica.
Celem pracy było porównanie wyników oznaczenia CgA badanej w surowicy i w osoczu metodą IRMA i ELISA.
Materiał i metody: Do badań porównawczych użyto 122 próbek osocza (EDTA) i 122 próbek surowicy, w których stężenie CgA oznaczo-
no metodą IRMA, 20 próbek osocza EDTA i 20 próbek surowicy — metodami IRMA i ELISA, 25 próbek osocza EDTA i 25 próbek osocza
heparynowego — metodami IRMA i ELISA oraz 8 próbek osocza EDTA, osocza heparynowego i surowicy metodami IRMA i ELISA.
Materiał do porównania uzyskano z jednoczasowego pobrania krwi od tych samych osób (ochotników i pacjentów z NET).
Stężenie CgA oznaczono zestawami odczynników firmy CIS bio International (Francja).
Wyniki: Stężenie CgA w osoczu było istotnie wyższe niż w surowicy. Różnice te w przedziale stężeń 10–100 ng/ml wyniosły 20–70%
(mediana 61 v. 42), w zakresie 101–300 ng/ml wyniosły 12–60% (mediana 147 v. 101), natomiast przy stężeniach 301–1076 ng/ml wyniosły
14–40% (mediana 486 v. 356). Stężenia CgA mierzone w tych samych próbkach metodami IRMA i ELISA były zbliżone, aczkolwiek różnice
między oznaczeniami w surowicy i w osoczu były trochę mniejsze w metodzie ELISA. Nie stwierdziliśmy natomiast istotnych różnic
między stężeniami CgA badanego w osoczu heparynowym i w osoczu EDTA.
Wnioski: Odnosząc każdy indywidualny wynik CgA do podanego zakresu referencyjnego (albo punktu odcięcia), musimy mieć na
uwadze to, czy materiałem do badania było osocze czy surowica. (Endokrynol Pol 2010; 61 (4): 346–350)
Słowa kluczowe: chromogranina A, CgA, CgA-IRMA, CgA-ELISA, guzy neuroendokrynne
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Introduction
Chromogranin A (CgA) is a 49-kDa acidic glycoprotein
[1]. CgA is physiologically released by exocytosis, and
can be detected in blood [2, 3].
The first immunoassay for detection of circulating
CgA levels in blood was a RIA method developed in
1984 by O’Connor and Bernstein. In 1989, Dillen et al.
developed an EIA method with enzyme-conjugated
CgA. Further works applied sandwich methods using
two monoclonal or polyclonal antibodies [4–7].
Chromogranin A (CgA) is regarded as a major, non-
specific marker of neuroendocrine tumours (NET). Its
estimation appears helpful for diagnostic purposes and
is particularly useful for monitoring the treatment of
NET [8–11]. It must be kept in mind, however, that var-
ious factors, drugs, or coexisting diseases may influence
the outcome of CgA measurement in blood [12]. One
such analytical factor is the sort of studied biological
material, whether it is plasma or serum [13].
 The aim of our study was to compare the results of
CgA measurements in serum, plasma-EDTA, and plasma-
heparin using commercial IRMA and ELISA methods.
Material and methods
The materials for our study were serum, plasma-EDTA,
and plasma-heparin samples obtained from the same
blood collections in healthy volunteers and patients di-
agnosed for the possible presence of NET or being mon-
itored during specific treatment for GEP-NET, carcino-
id, pheochromocytoma, adrenal carcinomas, or MEN
syndromes.
Venous blood samples were drawn into tubes con-
taining EDTA, heparin, or clot activator, centrifuged at
4°C (1500–2000 g) for 15 minutes, then plasma and se-
rum were separated and stored at –20°C until assayed.
We analysed 122 samples of EDTA-plasma and
122 samples of serum by IRMA method, 20 samples of
EDTA-plasma and 20 samples of serum by IRMA and
ELISA methods, 25 heparinised plasma samples and
25 samples of EDTA-plasma by IRMA and ELISA meth-
ods, and 8 EDTA-plasma, heparinised-plasma, and se-
rum samples by IRMA and ELISA methods.
CgA was measured with the use of kits manufac-
tured by CIS bio International (France). In both meth-
ods a recombinant human CgA was used as standard,
and the applied monoclonal antibodies recognized the
central domain of the molecule aa. 145–245 (intact CgA),
and probably only some of the circulating CgA frag-
ments. The detection limit of IRMA is 1.5 ng/mL, and
that of ELISA is 2.6 ng/mL. The reference value for the
IRMA method proposed by the manufacturer (calcu-
lated on a group of 162 volunteers) in serum samples is
19.4–98.1 ng/ml (median 41.6) and for plasma-EDTA (cal-
culated on a group of 50 volunteers) it is supposed to
be in the range 20–150 ng/mL (median 56) (those latter
data were obtained from the CIS website). The refer-
ence value for the ELISA CIS method, as determined
only for serum samples on a group of 114 healthy sub-
jects, was 27–94 ng/mL (median 44).
The study was approved by the Ethical Committee
at the Medical Centre for Postgraduate Education.
All results are expressed as median and arithmetic
mean ± SD. Differences between the groups are pre-
sented as percentages.
Results
Table I presents the results of CgA concentrations as
measured by IRMA in plasma-EDTA and serum sam-
ples of 122 patients in 3 ranges of concentrations. In the
range 10–100 ng/mL, the difference between plasma-
EDTA and serum was 20–70% (median 61 v. 42), in the
Table I. The differences in chromogranin A (CgA) concentrations measured in plasma-EDTA and serum by IRMA method in
three concentration ranges
Tabela I. Różnice w stężeniu chromograniny (CgA) oznaczanej w osoczu EDTA i surowicy metodą IRMA w trzech zakresach
stężeń
n= 122  Plasma-EDTA Serum  Difference (%)
 10–100 ng/mL  83  x = 73 ng/mL  x = 56 ng/mL 20–70% plasma-EDTA >> serum
SD = 48 SD = 42 (x = 46%)
median = 61 median = 42
101–300 ng/mL 28  x = 157 ng/mL x = 117 ng/mL 12–60% plasma-EDTA >> serum
SD = 127 SD = 128 (x = 36%)
median = 147 median = 101
301–1076 ng/mL  11  x = 541 ng/mL x = 416 ng/mL 14–40% plasma-EDTA > serum
SD = 233 SD = 203 (x = 31%)
median = 486 median = 356
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range 101–300 ng/mL, the difference was 12–60% (me-
dian 147 v. 101) and in the range 301–1076 ng/mL it was
14–40% (median 486 v. 356).
Table II presents the results of CgA concentrations
as measured by both IRMA and ELISA methods in the
other 20 patients. The concentration of CgA appeared
higher in plasma-EDTA than serum, and the difference
was 12–48% (median 249 v. 184) for the IRMA method,
and 4 –33% (median 251 v. 222) for ELISA.
 The Table III shows the CgA results in plasma-EDTA
and plasma-heparin samples of 25 patients as measured
by IRMA and ELISA methods. By IRMA method, the
median CgA concentrations for plasma-EDTA and plas-
ma-heparin were 87 v. 88 (the difference was between
1–8%). By ELISA method, the median concentrations
were 76 v. 83 only in 6 of 25 cases (only in 6 of 25 cases
this difference was 12–34%).
 In the group of healthy volunteers (Table IV), the
median concentrations of CgA in plasma-EDTA and
plasma-heparin for IRMA method were 49 v. 47, and
for the ELISA methods, the median was 35 v. 41, whereas
the differences between CgA concentrations in plasma-
EDTA and serum samples were 28–76% (median 49 v. 34)
for IRMA and 22–68% (median 35 v. 19) for ELISA,
respectively.
Discussion
Currently, blood CgA levels can be measured using three
methods: IRMA, ELISA, and RIA. Comparing the CgA
concentration in serum and plasma, obtained at the same
time from the same subjects, we observed higher levels
in plasma than in serum, regardless of the analytical
method used (IRMA or ELISA of the same producer).
In general, all commercially available CgA kits are
characterized by relatively high specificity for CgA
molecules (intact) but may differ slightly in the matter
of recognition of the CgA fragments or aggregates.
The questions arise:
1. Should current analytical tests recognize mainly in-
tact CgA or both the intact sequence and major frag-
ments of CgA?
2. What is the cause of the observed differences in the
concentrations of CgA tested in plasma and serum?
3. Could it be due to the different stability of the CgA
in the environment of plasma and serum?
Table II. The differences in chromogranin A (CgA) concentrations measured in plasma-EDTA and serum by IRMA and ELISA
methods
Tabela II. Różnice w stężeniu chromograniny A (CgA) oznaczanej w osoczu EDTA i surowicy metodą IRMA i ELISA
IRMA  ELISA
 Plasma-EDTA  Serum Plasma-EDTA Serum
n = 20 n = 20 n = 20 n = 20
x = 329 ng/mL x = 254 ng/mL x = 353 ng/mL  x = 308 ng/mL
SD = 247  SD = 205 SD = 261 SD = 243
median = 249 median = 184 median = 251 median = 222
12–48% 4–33%
plasma > serum plasma > serum
Table III. The differences in chromogranin A (CgA) concentrations measured in plasma-EDTA and plasma-heparin by IRMA
and ELISA methods
Tabela III. Różnice w stężeniu chromograniny A (CgA) oznaczanej w osoczu EDTA i osoczu heparynowym metodą IRMA
i ELISA
IRMA  ELISA
 Plasma-EDTA Plasma-heparin  Plasma-EDTA Plasma-heparin
n = 25 n = 25 n = 25 n = 25
 x = 158 ng/mL x = 161 ng/mL  x = 140 ng/mL x = 145 ng/mL
SD = 192 SD = 196 SD = 193 SD = 203
median = 87 median = 88 median = 76 median = 83
1–8% 1–14%*
plasma-EDTA = plasma-heparin plasma-EDTA ª plasma-heparin
 *in a few cases the difference amounted 12–34%
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Chromogranin A is a calcium-binding protein and
can aggregate at high concentrations of free Ca2+ ions,
so the measured CgA blood level could be affected by
the presence of such Ca2+ ions [14, 15]. Anticoagulation
occurs through the binding of Ca2+ ions and the inhibi-
tion of thrombin action, whereas in venous blood sam-
ples drawn into tubes containing clot activator, the cal-
cium ions remain free. We suppose that the possible
reason for the detected differences could be a partial
aggregation of CgA in the environment of free calcium
ions, which can be prevented by the presence in the
samples of EDTA or heparin. Another possible expla-
nation for the noted differences is that some small CgA
fragments might be bound by the particles of a clot ac-
tivator used in serum samples.
 Modlin IM et al. (2010) mention in their paper that
CgA measurements in serum and plasma are concor-
dant [16]; however, from the work of Woltering EA et
al. (2006) [17,18] (from Fig. 1) cited by them in that mat-
ter, it appears that although correlation is high, the CgA
levels in plasma are c. 50% higher than in serum.
Our study showed that the difference between CgA
plasma and serum levels amounted to 20–70% (higher
levels were observed in plasma samples), whereas in
general there was no  significant difference in the CgA
concentrations measured in EDTA and the heparin plas-
ma environment.
 Another important matter is an appropriate cut-off
value, which to some extent should be adjusted to the sort
of biological material used (whether it is serum or plas-
ma). The producer of the assay kits, CIS bio, set the upper
value for serum at 98 ng/mL for IRMA and 94 ng/mL for
ELISA, whereas for plasma-EDTA it is set at 150 ng/mL
(from website information). So the cut off value for
plasma CgA is about 50% higher than for the serum
samples.
Other authors accepted a cut-off value for the se-
rum similar to that specified by the kit manufacturer.
Leon A et al. (2005) [19] determined the cut-off value to
be 87 ng/mL for the IRMA method, whereas the Italian
group of authors (2007) [20] proposed a cut-off value of
53 ng/mL for the same IRMA method despite the fact
that in 95% of their control subjects the upper limit was
86 ng/mL. Both of the above-mentioned authors mea-
sured the concentrations of CgA only in serum. How-
ever, Bìlek R et al. (2008) [21], who measured the con-
centration of CgA in EDTA-plasma of patients with
pheochromocytoma by ELISA, adopted the value of the
cut-off level at 130 ng/mL. This value is also c. 50% high-
er than that proposed by Leon A et al. for the serum
samples and lower than that suggested by the CIS man-
ufacturer for plasma samples. This matter needs fur-
ther evaluation on larger groups of patients and healthy
subjects.
At this time, the question arises whether we should
perform measurements of CgA only either in plasma-
EDTA or in heparinised-plasma, or the serum samples
are good as well. We think that the results of the CgA
determination in serum, although lower than in plas-
ma, are clinically useful too, provided the appropriate
reference range is adopted (especially cut-off value), and
the numerous other causes of elevated CgA levels in
blood are considered.
Conclusions
1. We found significant differences in the concentra-
tions of CgA measured in plasma and in serum, both
by IRMA and ELISA methods.
2. No marked differences in the determinations of CgA
concentration in EDTA-plasma and heparinised-
plasma were observed.
Table IV. The chromogranin A (CgA) concentrations measured in plasma-EDTA, plasma-heparin, and serum in a healthy
volunteer group by IRMA and ELISA methods
Tabela IV. Stężenie chromograniny A (CgA) oznaczane w osoczu-EDTA, osoczu heparynowym i surowicy w grupie zdrowych
ochotników metodą IRMA i ELISA
IRMA  ELISA
Plasma-EDTA Plasma-heparin Serum Plasma-EDTA Plasma-heparin Serum
 n = 8  n = 8  n = 8  n = 8  n = 8  n = 8
 x = 46 ng/mL x = 43 ng/mL x = 33 ng/mL  x = 38 ng/mL x = 42 ng/mL x = 27 ng/mL
SD = 17 SD = 15 SD = 13 SD = 13 SD = 12 SD = 14
median = 49 median = 47 median = 34 median = 35 median = 41 median = 19
2–6% 3–9%*
28–76% 22–68%
*in two cases the difference amounted to 25%
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3. To have valid and comparable results, it is obligato-
ry to measure CgA concentrations in the same sort
of material using the same method, preferably in the
same laboratory, and taking into account various
factors potentially affecting its concentration in
blood.
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